Millennium Management LLC Has $1.97 Million Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)

Millennium Management LLC grew its stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 160.2% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 90,436 shares of the company's stock after buying an additional 55,682 shares during the period. Millennium Management LLC owned approximately 0.31% of Dianthus Therapeutics worth $1,972,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. FMR LLC lifted its position in shares of Dianthus Therapeutics by 0.8% in the fourth quarter. FMR LLC now owns 4,439,281 shares of the company's stock worth $96,776,000 after buying an additional 36,133 shares during the last quarter. TCG Crossover Management LLC acquired a new stake in shares of Dianthus Therapeutics in the fourth quarter worth about $32,735,000. Braidwell LP lifted its position in shares of Dianthus Therapeutics by 144.4% in the fourth quarter. Braidwell LP now owns 1,206,589 shares of the company's stock worth $26,304,000 after buying an additional 712,902 shares during the last quarter. Alliancebernstein L.P. lifted its position in shares of Dianthus Therapeutics by 13.4% in the fourth quarter. Alliancebernstein L.P. now owns 1,159,776 shares of the company's stock worth $25,283,000 after buying an additional 136,633 shares during the last quarter. Finally, Janus Henderson Group PLC lifted its position in shares of Dianthus Therapeutics by 14.4% in the fourth quarter. Janus Henderson Group PLC now owns 1,085,648 shares of the company's stock worth $23,607,000 after buying an additional 136,314 shares during the last quarter. Institutional investors and hedge funds own 47.53% of the company's stock.

Dianthus Therapeutics Price Performance

Shares of NASDAQ DNTH traded up $0.28 during trading hours on Friday, hitting $18.85. 370,376 shares of the company's stock were exchanged, compared to its average volume of 277,206. Dianthus Therapeutics, Inc. has a 1-year low of $13.37 and a 1-year high of $32.27. The stock has a market capitalization of $606.22 million, a price-to-earnings ratio of -7.54 and a beta of 1.48. The company's 50-day moving average price is $18.90 and its 200-day moving average price is $21.24.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.82) EPS for the quarter, beating the consensus estimate of ($0.86) by $0.04. The firm had revenue of $1.16 million during the quarter, compared to analysts' expectations of $0.81 million. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. On average, research analysts expect that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have weighed in on DNTH shares. Wedbush reaffirmed an "outperform" rating and issued a $36.00 price target on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Guggenheim reissued a "buy" rating and set a $84.00 price objective on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. HC Wainwright reissued a "buy" rating and set a $40.00 price objective on shares of Dianthus Therapeutics in a research report on Tuesday, May 13th. Finally, Robert W. Baird cut their price objective on Dianthus Therapeutics from $58.00 to $50.00 and set an "outperform" rating for the company in a research report on Tuesday, May 13th. Seven equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, Dianthus Therapeutics currently has a consensus rating of "Buy" and a consensus price target of $53.00.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.